Palbociclib联合来曲唑作为雌激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌一线治疗的延长随访研究

Rugo等人（周四）研究了这一问题。

www.synapsesocial.com/papers/69d8d9b0d2f7327e70ae46b3 — DOI: https://doi.org/10.1007/s10549-018-05125-4

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. EuroQol - a new facility for the measurement of health-related quality of life· 1990 · 15,747 citations
2. Ribociclib Extends Survival in HR+ Breast Cancer· 2017 · 2 citations
3. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology· 2017 · 1,369 citations
4. A small sample study of the STEPP approach to assessing treatment–covariate interactions in survival data· 2009 · 47 citations
5. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study· 2014 · 1,903 citations